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Three TNF-A-INhIbITorS For TreATMeNT oF rheuMAToId ArThrITIS, 
ANkyloSINg SPoNdylITIS ANd PSorIATIc ArThrITIS
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Objectives: To perform pharmacoeconomic analysis of golimumab (GOL) vs 
adalimumab (ADA) and infiliximab (INF) for rheumatoid arthritis (RA), ankylosing 
spondylitis (AS) and psoriatic arthritis (PA) in Russia MethOds: Indirect compar-
ison demonstrated that compared drugs have similar efficacy and safety. Cost-
minimization analysis was performed to compare the cost for 1-year treatment with 
GOL, ADA and INF in doses according to the approved recommendations. Expected 
cost for treating all eligible patients with RA, AS and PA with TNF-α -inhibitors in 
Russia were calculated in a model, assuming that INF is used in the 1st line therapy 
during one year and ADA or GOL in the 2d line therapy during the 2d year. Number 
of patients to be treated with TNF-α -inhibitors was calculated based on state sta-
tistical data and data on the percentage of patients who do not respond to therapy 
with synthetic disease-modifying antirheumatic drugs (DMARDs) and first-line 
biologic DMARDs from clinical trials. Results: INF dosing regimen is different 
for RA and other rheumatic diseases, 1 year treatment with INF costs € 16,212 for 
RA and € 24,319 for AS and PA. GOL and ADA have the same dosing regimen for all 
rheumatic diseases and costs € 16,544 and € 24,243 per year correspondingly. If all 
eligible patients with rheumatic diseases in Russia receive biologic DMARDs when 
necessary, treatment with GOL in the 2d line is less expensive than ADA, difference 
in costs is € 89,062,427 (for all eligible patients per year). It allows treating additional 
4959 patients RA, 278 AS patients and 147 PA patients per year. cOnclusiOns: GOL 
is cost-saving vs ADA for the 2d line therapy of rheumatic diseases in Russia. 1-year 
treatment with GOL is less expensive that INF for AS and PA and may be considered 
as the 1st line option.
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Objectives: to conduct a pharmacoeconomic analysis of abatacept vs etaner-
cept, tocilizumab and adalimumab for rheumatoid arthritis (RA) in adult patients, 
resistant to methotrexate therapy, in Russia. MethOds: Indirect comparison of 
clinical efficacy of abatacept, etanercept, tocilizumab and adalimumab was per-
formed. Data on safety from clinical studies and meta-analysis was analyzed. The 
differences in the direct medical costs for compared biological drugs (BD) in adult 
patients with RA were calculated using the cost-minimisation analysis. The cost 
of abatacept vs etanercept and tocilizumab were calculated on the basis of the 
registered manufacture’s prices for vital and essential drugs (VED) in 2012. The 
costs of abatacept vs adalimumab were calculated based on the price of tender 
purchases in 2011 (adalimumab is not included into the VED List, and its price is 
not registered). The costs of day care for patients during the BD administration 
were calculated based on the cost norms per volume of medical care approved by 
the Program of State Guarantees for the provision of free medical care to Russian 
citizens in 2012. The calculations were performed over the BD application period 
for 2 years. Results: Indirect comparison showed no statistically significant dif-
ferences in the efficacy of compared BD. There was no data about clinically mean-
ingful differences in safety. The use of abatacept is less costly than etanercept 
and tocilizumab when registered manufacture’s prices are used for cost estima-
tion. The difference in costs (in favor of abatacept) amounted to 1431.34 EUR and 
16058.34 EUR per patient per 2 years respectively. Abatacept is less costly than 
adalimumab (the costs are calculated based on prices of tender purchases in 2011): 
the difference in costs amounted to 1502.07 EUR per patient per 2 years in favor 
of abatacept. cOnclusiOns: Abatacept is a cost-saving option compared with 
etanercept, tocilizumab and adalimumab.
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curreNT ANd FuTure STrATegy For oSTeoPoroSIS ScreeNINg ANd 
dIAgNoSTIcS: coST-eFFecTIveNeSS oF FrAx wITh or wIThouT PulSe-
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Objectives: Over 75% of osteoporotic patients are not diagnosed with osteoporo-
sis and do not receive treatment because effective on-site diagnostics is lacking in 
primary care facilities. We compare the cost-effectiveness of two pathways of osteo-
porosis diagnosis: 1) Fracture Risk Assessment Tool (FRAX) followed by pocket size 
pulse-echo ultrasound device (Bindex®) followed by Dual-energy X-ray absorptiom-
etry (DXA) when needed (“proposed”), and 2) FRAX followed by DXA when needed 
(“guideline”). MethOds: A new Markov model of preventive osteoporosis treatment 
(assumptions: generic alendronate treatment; efficacy based on published meta-
analysis and modified by compliance/persistence; wrist, vertebral, hip and other frac-
tures included; Finnish health care payer perspective with 10-year timeframe and 3% 
discounting per annum) was extended to include the proposed pathway and osteo-
porosis screening/diagnosis in terms of sensitivity/specificity. FRAX with body mass 
index and age dependent National Osteoporosis Guideline Group thresholds was the 
initial screening tool common to both pathways. Bindex® was calibrated to 90% sen-
sitivity and specificity thresholds (International Society for Clinical Densitometry). In 
the proposed pathway, only the patients with Bindex result between these calibration 
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Objectives: Systemic Lupus Erythematosus (SLE) is a chronic non-organ spe-
cific autoimmune disease and is characterized by a dysregulation of the immune 
system that involves many organs and systems. It affects about 28,500 people 
in Italy, especially women of childbearing age (female-male ratio 9:1) that may 
have a compromised functional state and a decreased quality of life. The purpose 
of this analysis is to determine the cost-effectiveness of belimumab, a new bio-
logical treatment specifically developed for the treatment of SLE, in the Italian 
setting. MethOds: A cost-effectiveness micro simulation model with a lifetime 
horizon was adapted to the Italian setting. The analysis compares the standard 
of care (SoC) alone vs belimumab plus SoC from the perspective of the National 
Healthcare System. Clinical-economic consequences of the therapy and of the 
development of organ damage were calculated. When available, Italian data were 
used, otherwise UK costs were transformed into euros using the purchasing-power 
parity approach. The utility values were based on the EQ-5D of belimumab clini-
cal trials (BLISS 52 and 76). The results were discounted by 3% for both costs and 
effects. It was considered a duration of treatment with belimumab of 6 years and 
it was assumed that the drug is used with wastage. Results: The results of the 
cost-effective analysis in terms of cost per life year gained (ICER) and cost per QALY 
(ICUR) were € 22,990 and € 32,859 respectively. These values drop to € 20,119 and 
€ 28,754 respectively when indirect costs are included. cOnclusiOns: In this 
analysis, the results of ICER and ICUR show that belimumab is cost-effective in 
the Italian setting, according to the guidelines of the Italian Association of Health 
Economics (€ 25-40,000/QALY).
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Objectives: To evaluate the cost-effectiveness of tocilizumab (TCZ) in the treat-
ment of polyarticular juvenile idiopathic arthritis (pJIA) in the United Kingdom 
(UK). MethOds: An individual sampling model was developed to reflect the health 
care system and treatment pathway in the UK. Benefits were measured in terms of 
Quality Adjusted Life years (QALYs) and were derived from HUI3 data collected by 
the Dutch Arthritis and Biologicals in Children (ABC) Register [Prince et al., 2011]. 
Costs were calculated from a National Health Service and Personal Social Services 
perspective. The analysis calculated incremental costs and benefits associated with 
the addition of first line TCZ to the standard care pathway involving etanercept 
(ETN), adalimumab (ADA), and abatacept (ABA). The economic model used efficacy 
inputs derived from an indirect comparison of TCZ and ADA [Sawyer et al., 2013]. 
Due to fundamental differences in the clinical trial populations and trial design, it 
was not possible to compare the response rates of TCZ with ETN and ABA. Therefore 
in the absence comparative data, the economic analysis assumed response rates 
for ETN and ABA were similar to ADA. Longer-term treatment discontinuation was 
linked to level of response and assumed to be independent of treatment. Results: 
Base case results estimated incremental costs of approximately £1,750 and incre-
mental QALYs of 0.1011. The incremental cost-effectiveness ratio (ICER) was £17,000 
per QALY gained. cOnclusiOns: The results of this analysis suggest that TCZ rep-
resents an efficacious and cost-effective addition to the current standard of care for 
treating pJIA patients in the UK.
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Objectives: To compare the cost of using subcutaneous abatacept (SC ABA) versus 
other first-line biological disease-modifying antirheumatic drugs (DMARDs) avail-
able in Spain, in the treatment of patients with rheumatoid arthritis (RA) who have 
failed an initial treatment with methotrexate (MTX). MethOds: With regards to 
efficacy and safety outcomes, SC ABA was considered non-inferior vs intravenous 
ABA (IV ABA), adalimumab (ADA), certolizumab pegol (CZP), etanercept (ETN), goli-
mumab (GLM), infliximab (IFX) and tocilizumab (TCZ), based on results of an indirect 
comparison using mixed treatment analysis. Therefore a cost- minimization analy-
sis for a 3 year time horizon was developed. The perspective was that of the Spanish 
National Health System (NHS). Pharmaceutical and administration costs (€ , 2013) of 
all biological DMARDs which are available in Spain as first-line treatment after MTX 
were considered. Drug costs were included in terms of ex-factory price with man-
datory rebate. Administration costs were obtained from local published data. The 
analysis was developed for an average patient weight of 70 kg. A 3% annual discount 
rate was applied. Deterministic and probabilistic sensitivity analyses were per-
formed. Results: SC ABA treatment was associated with a yearly cost of € 11,521.36 
per patient during the first year of treatment and € 11,002.23 in subsequent years. 
The total 3-year cost of SC ABA was € 32,138.43 per patient, proving to be cost saving 
versus most of the other biological DMARDs. In all cases, pharmaceutical costs lead 
to more than 85% of total disease management costs. Sensitivity analyses proved 
the model to be robust. cOnclusiOns: According to these results, SC ABA would 
lead to cost-savings versus IV ABA, ADA, CZP, ETN, GLM and TZC in the management 
of RA patients initiating treatment with biological DMARDs.
